Markets

3D Printing Notches Another Major Healthcare Breakthrough

Source: Organovo Holdings.

Engineering human tissue has always been a dream of drug developers, as it could mean the rapid study of clinical pharmacokinetics. The idea behind having the ability to test on human tissues is that it could save millions upon millions of dollars in testing costs, but it could also greatly reduce the amount of guessing spent on whether or not a drug would be toxic to a patient. Organovo's 3D liver assay allows researchers to work with bioengineered human liver samples and do just this.

In its first quarter on the market exVive3D brought in nearly $140,000 when you include product and service revenue. Previously, Organovo's revenue had been entirely tied to collaborative research. Although this sales figure might be a bit low for most investors' expectations, it's possible that drug developers and researchers are simply waiting for more feedback from their peers before taking the dive themselves.

Source: Flickr user Umberto Salvagnin.

Bioengineered human liver tissue is just the beginning . Recently, Organovo and the Yale School of Medicine announced a collaboration, which is being funded by the Methuselah Foundation, to combine Organovo's bioprinting technology with Yale's top researchers to create transplantable organs. While taking this from concept to reality is a slow process, if organs could be bioengineered on a mass scale at some point in the future, we could eliminate organ donor waiting lists!

This will take time

I really enjoy scientific breakthroughs, and the news this week out of Tufts University and the University of Pavia is encouraging. It certainly validates that what Organovo is doing on a larger scale could very well succeed. However, from the viewpoint of an investor, it could be many years before Organovo can turn that success into consistent profits.

Probably the biggest factor working in Organovo's favor is its unique technology. That alone could lead to a number of upfront cash payments as drug developers look to partner with Organovo to develop new therapies (or in the case of Yale, transplantable organs).

But for the time being I'd suggest that playing it cautious is probably the smartest thing investors can do. It's worth closely monitoring Organovo and other 3D advances in the healthcare arena, but it's just too early for this area to be a viable investment opportunity.

This coming blockbuster will make every biotech jealous

The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that could revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. If you hope to outsmart Wall Street and realize multi-bagger returns, you will need to get in early -- check out The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. CLICK HERE NOW .

The article 3D Printing Notches Another Major Healthcare Breakthrough originally appeared on Fool.com.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong , track every pick he makes under the screen name TrackUltraLong , and check him out on Twitter, where he goes by the handle @TMFUltraLong .The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ONVO

Other Topics

Stocks

Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More